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Summary
Background: A universal hallmark of cancer cells is the change in their glycosylation phenotype. One of the most
frequent alterations in the normal glycosylation pattern observed during carcinogenesis is the enhancement of a
(1,6)linked fucose residues of glycoproteins, due to the up-regulation of the a(1,6)fucosyltransferase activity. Our
previous results demonstrated the specific alteration of this enzyme activity and expression in colorectal cancer,
suggesting its implication in tumour development and progression.
Methods: In the current work we combined a LCA-affinity chromatography with SDS-PAGE and mass spectrometry
in order to identify a(1,6)fucosylated proteins differentially expressed in colorectal cancer. This strategy allowed the
identification of a group of a(1,6)fucosylated proteins candidates to be involved in CRC malignancy.
Results: The majority of the identified proteins take part in cell signaling and interaction processes as well as in
modulation of the immunological response. Likewise, we confirmed the increased expression of GRP94 in
colorectal cancer tissue and the significant down-regulation of the IgGFcBP expression in tumour cells.
Conclusion: All these results validate the importance of core-fucosylated proteins profile analysis to understand the
mechanisms which promote cancer onset and progression and to discover new tumour markers or therapeutic
targets.
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Background
Colorectal carcinoma (CRC) is one of the most frequent
t u m o u r si nt h eW e s t e r nw o r ld. Although early stages
are successfully treatable, many cases are undiagnosed
until late stages when the prognosis is poor [1]. There-
fore, the identification and verification of proteins that
have a functional role in the patho-physiology of CRC
remains an important goal to discover new biomarkers
for diagnosis, prognosis and follow-up, as well as to find
therapeutic targets.
Glycosylation plays fundamental roles in controlling
various biological processes such as embryonic develop-
ment, immune response and cell-cell interactions
involving sugar-sugar or sugar-protein specific recogni-
tion [2]. An universal hallmark of cancer cells is the
change in their glycosylation phenotype, with several
effects on this tumour cells behavior [3]. In this sense,
glycosylation analysis has become an important target
for proteomic research and has reached great interest to
understand the molecular events associated with tumour
development and progression.
One of the most frequent alterations in the normal
glycosylation pattern observed during carcinogenesis is
the enhancement of a(1,6)linked fucose residues of gly-
coproteins [4,5]. The enzyme responsible of this fucosy-
lation step is the a(1,6)fucosyltransferase [FUT8, a(1,6)
FT], which catalyzes the transfer of a fucose residue
from GDP-fucose to the innermost GlcNAc of hybrid
and complex N-linked oligosaccharides via a(1,6)linkage.
Numerous studies have demonstrated the key role of a
(1,6)fucosylation in the activity of proteins strongly
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TGFR-b1 or VEGFR-2 [6-8], and tumour dissemination,
for example, E-cadherin or a3b1a n da5b1 integrins
[9-11]. In addition, several a(1,6)fucosylated proteins
have been proposed as potential biomarkers for different
types of tumours. The most representative case is the a
(1,6)fucosylated fraction of a-fetoprotein (AFP-L3), cur-
rently employed as a specific tumour marker for hepato-
carcinoma (HCC) [12]. Other aberrantly core-
fucosylated proteins such as GP73, haptoglobin (Hp),
transferrin, a-1-acid glycoprotein or a-1-antitrypsin,
have also been reported as promising serum biomarkers
for HCC [13,14]. Moreover, an important elevation of
serum fucosylated forms of Hp and RNase1 has been
described in pancreatic tumours [15,16].
The identification and validation of specific tissue and/
or serum a(1,6)fucosylated proteins which share altered
expression levels is of great value to clarify the insights of
the critical events in cancer progression. However, the
proteomic analysis of glycoproteins is tedious because it
requires their isolation from complex biological samples
that contain both non glycosylated and very heteroge-
neously glycosylated proteins [17]. Thus, the application
of different analytic approaches has revealed as the most
efficient tool to study the tissue or serum profile of these
proteins. In this sense, previous studies have achieved the
affinity purification of a(1,6)fucosylated proteins using
lectins that specifically recognize the (1,6)fucose linkage,
such as LCA (Lens culinaris agglutinin) [18] or AAL
(Aleuria aurantia lectin) [19], followed by separation
methods (HPLC or SDS-PAGE) and analytical LC-MS/
MS to identify the proteins differentially expressed and/
or fucosylated in cancer tissue [20,21].
We have previously reported the specific alteration of
a(1,6)FT activity and expression in CRC, suggesting its
implication in tumour development and progression
[22,23]. To complete the knowledge about the impor-
tance of the a(1,6)fucosylation in CRC, in the present
study we have undertaken an affinity enrichment
approach to compare the a(1,6)fucosylated proteins pro-
file of healthy and tumour colorectal tissues. This strat-
egy has allowed us the identification of several a(1,6)
fucosylated proteins as candidates to be involved in
CRC malignancy. In particular, we observed a significant
alteration of GRP94 and IgGFcBP expression levels in
colorectal cancer tissue. These results validate the
importance of core-fucosylated proteins profile analysis
in CRC as a way to discover new tumour markers or
therapeutic targets.
Methods
Human tissue samples
Paired colorectal tissue samples, both from tumour and
adjacent healthy mucosa, were obtained from patients
with CRC who underwent surgery at the University
Complex Hospital of Ourense, Spain. Mucosa was con-
sidered healthy if distant by at least 10 cm from the
tumour. The approval of the appropriate local Institu-
tional Review Board as well as the informed consent
from the patients, were obtained.
The specimens used for immunohistochemical analysis
were fixed in formalin (10%), embedded in paraffin (60°
C) and subjected to hematoxylin and eosin staining
(standard procedure) for evaluating their microscopic
features. The specimens employed for the chromatogra-
phy enrichment and Western/Lectin blot analysis were
washed with ice-cold saline buffer and stored frozen at
-85°C until use.
Protein extraction
Colorectal tissue was homogenized in 6 vol. of 0.01 M
Tris-HCl buffer (pH 7.4), containing 0.25 M sucrose, 1%
Triton X-100 and a cocktail of protease inhibitors
(Complete™ Mini tablets, Roche). The homogenate was
c e n t r i f u g e df o r1 0m i na t1 5 0 0 0 xg and 4°C. The super-
natant obtained was recovered and the protein concen-
tration of this final preparation (total fraction, TF) was
determined by BCA protein assay, using bovine serum
albumin as standard. The tissue extract was stored at
-20°C until use.
a(1,6)fucosylated proteins enrichment with LCA-affinity
chromatography
LCA-affinity chromatography was performed as pre-
viously described by Dai et al. [21] with some modifi-
cations. LCA column was prepared by adding 4 mL of
agarose-bound lectin (Sigma-Aldrich Aldrich) into
polypropylene columns (Econo Column, Bio-Rad). The
columns were equilibrated ab initio with Tris-HCl 0.05
M (pH 7.2). Once equilibrated, 1 mL of the total pro-
tein (TF) preparation was loaded onto the LCA col-
umn. After incubating for 10 min, the unbounded
proteins (FI) were washed out with 15 mL of equili-
brating buffer. The unspecific retained proteins (FII)
were then removed with 10 mL of Tris-HCl 0.05 M
(pH 7.2) containing NaCl 0.3 M. Finally, the specific
bounded fraction (FIII) was eluted using 10 mL of
Tris-HCl 0.05 M (pH 7.2) containing NaCl 0.3 M, a-
methyl-D-mannopyranoside 0.4 M and a-methyl-D-
glycopyranoside 0.4 M. The chromatographic process
was controlled by spectrophotometry at 280 nm with a
UVIKON 930 spectrophotometer (Kontron Instru-
ments). All fractions obtained were then centrifugated
in Amicon Ultra-4 Centrifugal Filters Devices (Milli-
pore) for concentrating and desalting. The protein
recovery of the lectin column was determined by
means of the BCA protein assay, using bovine serum
albumin as standard.
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20 and 10 μg of protein from total extraction (TF) and
FI, FII and FIII chromatography fractions were subjected
in parallel to SDS-PAGE (12% polyacrylamide gel) under
reducing conditions. The gel loaded with 20 μgo fp r o -
tein was stained with Coomassie Brilliant Blue R-250
(Bio-Rad). The proteins of the gel loaded with 10 g of
protein were electrotransferred onto a polyvinylidene
difluoride membrane (Hybond-P, Amersham
Bioscience). After blotting, the membrane was washed
with TBS containing 0.05% Tween-20 (T-TBS) (v/v),
blocked with 3% (w/v) dried serum albumin in T-TBS
overnight at 4°C, and incubated with 1/2,000 biotiny-
lated-LCA (Vector Laborato r i e s )f o r1ha tr o o mt e m -
perature. After washing with T-TBS, the blot was
incubated with 1/2,000 diluted Streptavidin-Alkalin
phosphatase (Sigma-Aldrich) for 1 h at room tempera-
ture. Finally, the blot was washed with T-TBS and the
colour was developed using BCIP/NBT Liquid Substrate
System (Sigma-Aldrich).
The band pattern and the intensity were obtained by
densitometric analysis (GS-800 Calibrated Densitometer,
Bio-Rad) using the Quantity One software for PC (Bio-
Rad). The relative intensity of FIII bands was employed
for comparative analysis between healthy and tumour
mucosa.
Protein identification by mass spectrometry
Differentially expressed bands present in FIII were
excised from gels and sent for analysis to the Proteo-
mics and Mass Spectrometry Facility at Parc Científic de
Barcelona (Barcelona, Spain).
Proteins were in-gel digested with trypsin (Sequencing
grade modified, Promega) in the automatic Investigator
ProGest robot of Genomic Solutions. Briefly, excised
gels spots were washed sequentially with ammonium
bicarbonate buffer and acetonitrile. Proteins were
reduced and alkylated by treatment with 10 mM DTT
solution during 30 min, and treatment with a 55 mM
solution of iodine acetamide, respectively. After sequen-
tial washings with buffer and acetronitrile, proteins were
digested overnight at 37°C with 0.27 nmol trypsin. Tryp-
tic peptides were extracted from the gel matrix with
10% formic acid and acetonitrile; the extracts were
pooled and dried in a vacuum centrifuge.
Tryptic peptides were analyzed by nano-electrospray
ionization MS/MS (ESI-Q-TOF) with a Q-TOF-Global
(Micromass-Waters). Samples were resuspended in 12
μL of a 10% formic acid solution, and 4 μL were injected
for chromatographic separation onto a reverse-phase
capillary C18 column (75 μm of internal diameter and 15
cm of length, PepMap column, LC Packings). The eluted
peptides were ionized via coated nano-ES needles (Pico-
Tip™, New Objective). A capillary voltage of 1,800-2,200
V was applied together with a cone voltage of 80 V. The
collision in the CID (collision-induced dissociation) was
20-35 eV with argon as collision gas. Data were generated
in a PKL file format, which were submitted for database
searching in the MASCOT server.
Western blot validation
20 μg of total protein preparation were subjected to
SDS-PAGE (12% polyacrylamide gel) and electrotrans-
ferred onto a polyvinylidene difluoride membrane
(Hybond-P, Amersham Bioscience). After blotting, the
membrane was washed with TBS containing 0.05%
Tween-20 (T-TBS) (v/v). The SNAPi.d. protein detec-
tion System (Millipore) was employed for the immuno-
detection. The membrane was blocked with 1% (w/v)
serum albumin in T-PBS for 10 min and incubated with
primary antibodies [mouse anti-GRP94 monoclonal anti-
body (3/1,000, Abcam), mouse anti-pIgR monoclonal
antibody (3/1,000, Santa Cruz Biotechnology) and rabbit
polyclonal anti-IgGFcBP (1/500, Sigma-Aldrich)] for 10
min at room temperature. After a wash with T-TBS, the
blot was incubated with 1/500 diluted secondary anti-
body, an alkalin-phosphatase-conjugated antibody
against mouse or rabbit IgG (Dako Cytomation), for 10
min at room temperature. Finally, the blot was washed
with T-TBS and the colour was developed using BCIP/
NBT Liquid Substrate System (Sigma-Aldrich).
Immunohistochemistry
Tissue sections (2-3 μm) were deparaffinized in xylene,
rehydrated in a graded ethanol series and incubated in
citrate buffer for 10 min in a microwave. Endogenous
peroxidase activity was blocked with 0.5% (v/v) hydro-
g e np e r o x i d ei nm e t h a n o l .A f t e rar i n s ei nP B S ,b o v i n e
serum was applied to block non-specific interactions.
Sections were then incubated 1 h with the primary anti-
body (rabbit polyclonal anti-IgGFcBP, 1/50, Sigma-
Aldrich) at room temperature. After a rinse in PBS, sec-
tions were incubated 10 min with the primary antibody
enhancer, and 1 h at room temperature with the sec-
ondary antibody bound to peroxidase. The peroxidase
reaction was visualized by incubating with DAB (3,3’-
diaminobenzidine). Finally, after a wash in water, the
sections were counterstained with haematoxylin, dehy-
drated in a graded ethanol series, washed in xylene and
mounted on a glass slide. Negative controls were per-
formed using PBS instead of the primary antibody. The
semiquantitative staining analysis was performed by
expert pathologists.
Statistical analyses
Statistical analyses were performed using SPSS v. 15.00
for WINDOWS XP. The results were considered signifi-
cant when p≤0.05.
Muinelo-Romay et al. BMC Cancer 2011, 11:508
http://www.biomedcentral.com/1471-2407/11/508
Page 3 of 12Results
Enrichment of a(1,6)fucosylated proteins from colorectal
tissues by LCA-affinity chromatography
The success of a comparative glycoproteomic approach
resides in the quality of the enrichment process. There-
fore, lectin affinity chromatography protocols are com-
monly used to isolate different types of glycoproteins. In
the present study, the lectin LCA, which recognizes a-
mannopyranosyl and a-glucopyranosyl terminal residues
of a(1,6)fucosylated proteins [18], was employed to
separate this group of proteins. After chromatography,
we obtained three distinct fractions: FI (which contains
non-retained proteins), FII (composed of unspecific
retained proteins and FIII, mainly enriched in a(1,6)
fucosylated proteins). Five paired samples of healthy
mucosa and tumour tissue were submitted to this pre-
fractionation procedure, being the chromatography pro-
file (Figure 1A and 1B) and the protein recovery very
similar from both tissues (Table 1).
Proteins from the crude extract (TF) and the chroma-
tography fractions were analyzed by means of 1D-SDS-
PAGE and lectin blot. The majority of the proteins
observed in TF were eluted in FI (Figure 2, left). In both
fractions we detected a strong band of about 60 kDa
corresponding to albumin. The elimination of the albu-
min-associated band (a non-glycosylated protein),
allowed the visualization of minority proteins in FII and
FIII (Figure 2A). Additionally, in the fraction enriched
with a(1,6)fucosylated proteins, FIII, bands not visua-
lized in the previous fractions were observed (Figure
2B), as well as others hardly expressed in FI and FII
(Figure 2C). This electrophoretic profile ratified the
appropriate functioning of the prefractionation proce-
dure. Likewise, the lectin blot confirmed the enrichment
of a(1,6)fucosylated proteins in FIII, since a higher
number of LCA-reactive bands was observed in compar-
ison to the other fractions (Figure 2, right).
Comparison of 1D-SDS-PAGE pattern of a(1,6)fucosylated
proteins from healthy and tumour colorectal mucosa
With the aim to identify the a(1,6)fucosylated proteins dif-
ferentially expressed in healthy and tumour colorectal
mucosa, the band profile of the FIII fraction after the 1D-
SDS-PAGE was analyzed using the Quantity One Software
(Bio-Rad). The analysis compared the intensity level of the
detected and matched bands from paired tumour/healthy
specimens from 5 CRC patients. A total of 20 bands were
compared between healthy and tumour mucosa. Although
no statistically significant differences were found, some
bands showed a clear trend of increase or decrease in
tumour samples. In this sense, our interest was focused in
two bands, n° 5 and n° 8 (Figure 2A). The first one showed
a higher intensity in tumour compared to healthy mucosa
(+4.57 fold-change) in 4 of 5 patients, while the second
one showed a lower tumour intensity in 3 of 4 patients
(-18.80 fold-change). The two bands were excised and
submitted to mass spectrometry (MS) analysis.
Identification of a(1,6)fucosylated proteins by mass
spectrometry
The CapLC-n-ESI-Q-TOF method allowed us the iden-
tification of proteins present in the n° 5 and n° 8 bands.
The identity of these proteins and other characteristics,
such as the experimental relative molecular mass (Mr),
the score and the SwissProt/NCBInr accession number,
Figure 1 Chromatographic profile. Representative chromatographic
profile of a(1,6)fucosylated proteins enrichment from healthy (A) and
tumour (B) colorectal specimens.
Table 1 Protein recovery during LCA-affinity
chromatography
TF FI FII FIII
Healthy Mean (mg) ±
SEM
4.83 ±
0.67
2.54 ±
0.22
0.21 ±
0.07
0.33 ±
0.04
n = 5 Percentage (%) 100 52.62 4.27 6.81
Tumour Mean (mg) ±
SEM
5.38 ±
0.33
3.03 ±
0.50
0.28 ±
0.06
0.44 ±
0.05
n = 5 Percentage (%) 100 56.24 5.19 8.23
SEM, standard error of the mean
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5 candidate proteins with a score value higher than 37
(the limit to consider the identification of the protein
not accidental). The protein with the highest score was
the glucose regulated glycoprotein of 94 kDa (GRP94),
an endoplasmic reticulum chaperone which participates
in the maintenance of the cell homeostasis, specially
under stress conditions. The second candidate was the
polymeric Ig receptor (pIgR), responsible for the trans-
port of polymeric immunoglobulins (IgA and IgG)
across the mucose epithelial cells. The others candidates
were the adhesion vascular protein 1 (VAP-1), the
fibulin-1C and the platelet glycoprotein IIIa (GP IIIa),
implicated in cell adhesion, recognition process and the
immune response, respectively.
On the other hand, the highest scored candidate pro-
tein integrating the band n° 8 was the IgG Fc binding
protein (IgGFcBP), a secreted protein present in the
colon mucus. The other two proteins identified as
potential candidates were the heavy chain of IgGB12
and the Fc region of IgA-1, both implicated in the mod-
ulation of the cell immune mechanisms.
All of these candidate proteins are glycosylated and
some of them, such as pIgR, IgGFcBP, VAP-1 and the
Figure 2 Different expression of a(1,6)fucosylated proteins in healthy and tumour colorectal tissues. (A) Representative Coomassie
brilliant blue stained 1D-SDS-PAGE gel of the total protein fraction (TF) and the following chromatographic fractions obtained; FI (non-retained
proteins), FII (unspecific retained proteins) and FIII [a(1,6)fucosylated proteins] and the corresponding lectin blot in a pair of healthy and tumour
tissue. (B) Patern of bands obtained in the FIII fraction of a pair of healthy and tumour samples. Bands 5 and 8 were excised and submitted to
mass spectrometry (MS) analysis.
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lated proteins, therefore validate the efficiency of the
chromatography approach performed for the fractiona-
tion of specifically glycosylated proteins [18].
Validation of GRP94, pIgR and IgGFcBP alteration by
Western blot
In order to validate the results obtained by 1D-SDS-PAGE,
three proteins, GRP94, pIgR and IgGFcBP were chosen to
determine their expression in tumour and healthy neigh-
boring tissue. This selection was performed taking into
account their score and their possible implication in CRC
development and/or progression. The total protein frac-
tion (TF) of 20 paired samples was employed for Western
blotting detection of GRP94 and IgGFcBP, while for pIgR
we examined 12 patients. The analysis demonstrated
higher levels of GRP94 expression in the tumour tissue in
15 patients of the total analyzed (p = 0.01, according to
Wilcoxon’s test, Figure 3). On the other hand, the pIgR
was identified in the same band as GRP94, which showed
a higher intensity in tumour tissue. However, after the spe-
cific immunodetection of pIgR, no differences were
observed between the tumour and healthy mucosa (p =
0.87, according to Wilcoxon’s test, Figure 4). Finally, the
Western blot for IgGFcBP allowed the visualization of two
bands, corresponding to 108 and 52 kDa (Figure 5). The
expression of both isoforms decreased in the tumour tis-
sue of 13 and 12 patients, respectively, being this decrease
statistically significant for the 108 kDa isoform (p = 0.005
and p = 0.191 according to Wilcoxon’s test) (Figure 5). It
is also important to highlight that IgGFcBP was identified
in an electrophoretic band with lower levels of intensity in
tumour tissue.
Immuhistochemical analysis of IgGFcBP
Since the IgGFcBP histology distribution in CRC has not
been studied previously in order to assess how specific is
the alteration of its expression during the carcinogenesis
process 20 paired specimens of healthy and tumour
mucosa as well as 6 polyps, were analyzed by immuno-
histochemistry. The presence of the protein was
detected as a brown staining clearly localized in the
intracellular mucus of goblet cells (Figure 6A). A posi-
tive IgGFcBP expression was observed in all the healthy
specimens (Figure 6A), while in tumour only 3 cases
(early stage CRC) were positive (Figure 6B). In these
positive tumours, the IgGFcBP expression was confined
to the non-infiltrating epithelia. In addition, although all
tumour analyzed are no mucilaginous a higher muci-
nous component was observed in the 3 cases with posi-
tive IgGFcBP expression. The different IgGFcBP
immunohistochemical expression in tumour vs.h e a l t h y
tissue was statistically significant (p = 0.001, according
to Wilcoxon’s test). Furthermore, 4 of the polyps ana-
lyzed expressed the IgGFcBP; one hyperplastic, two ade-
nomatous, and one mixed of hyperplastic/adenomatous.
I n t e r e s t i n g l y ,t h ep o s i t i v eg l a n d sw e r ep l a c e di nt h e
non-dysplastic zones (Figure 6C).
Discussion
The scientific community shows an increasing interest
in qualitative and quantitative alterations that different
glycoproteins undergo during the malignant transforma-
tion process. This interest is fundamentally focused on
the detection of new tumour biomarkers for diagnosis,
prognosis and follow-up of the disease, as well as on the
development of new therapeutic targets. Thus, a large
Table 2 Identification of a(1,6)fucosylated proteins by mass spectrometry
Protein Band
n°
Mr
(kDa)
NCBInr Swiss-Prot
accession n°
Function Score Coverage
rate (%)
Glucose regulated glycoprotein
of 94 kDa
5 92.7 B4DHT9 Stress response/chaperone 743 20
Polymeric immunoglobulins
receptor
5 84.4 PO1833 Immune response 383 10
Vascular adhesión protein 1 5 85.1 Q16853 Cell adhesion molecule/Immune response 361 11
Fibulin-1 C 5 78.5 P23142-4 Extracellular matrix component/cell
adhesion and migration
339 12
Platelet glycoprotein IIIa 5 87.4 PO5106 Cell adhesion molecule/Immune response 156 5
IgG Fc binding protein 8 59.6 Q9Y6R7 Cell adhesion molecule/Immune response 1320 6
Unknown protein product 8 53.8 Q6ZVX0 unknown 343 24
Immunoglobulin G B12, heavy
chain
8 51.2 gi|15825648 Cell adhesion molecule/Immune response 272 16
Immunoglobulin a-1, constant
region
8 54.3 P01876 Cell adhesion molecule/Immune response 248 14
Each protein score represents the sum of the score of each ion protein analyzed and this is, in turn considered numerically as -10 * log (p), where p is the
probability that the matching was made randomly and coverage rate (%) represents the percentage of the total protein sequence that overlap with the peptide
fragments.
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kers are glycoproteins [24,25].
In particular, the study of the a(1,6)fucosylated pro-
teins expressed in tumour cells has achieved high
importance. Several researchers have reported the speci-
fic alteration of a(1,6)FT activity and expression in
malignant processes, such as HCC [26,27], thyroid papil-
lary carcinoma [28] and ovarian adenocarcinoma [29].
Recently, we have also reported the alteration of the
enzyme in CRC [22] and its implication in the disease
progression (submitted data). In this sense, it is impor-
tant to mention the critical role of a(1,6)FT activity in
the modulation of different growth factor receptors such
as EGFR, TGFbR or VEGFR. These molecules, strongly
implicated in the carcinogenesis process and considered
gold therapeutic targets for the treatment of solid
tumours, need to be core-fucosylated to activate their
intracellular signaling pathways [6-8]. Likewise, recent
reports have shown that a(1,6)fucosylation of different
adhesion molecules, such as adhesins or integrins, mod-
ify their functional activity, and could probably act as
relevant factors for the acquisition of the migratory phe-
notype by the epithelial tumour cells [6,10,11]. There-
fore, the identification and characterization of core-
fucosylated proteins differentially expressed in tumour
cells is considered of great usefulness to discover new
tumour biomarkers and therapeutic agents.
In the present study we combined a LCA-affinity
chromatography with SDS-PAGE and mass spectrome-
try in order to identify a(1,6)fucosylated proteins
Figure 3 GRP94 expression in healthy and tumour colorectal tissues. ( A )V a l i d a t i o no ft h e1 D - S D S - P A G Er e s u l t sf o rG R P 9 4b y
immunoblotting in 20 paired samples of healthy (H) and tumour (T) tissue. (B) Statistically significant increase of the GRP94 expression found in
tumour tissue. *p < 0.05, according to Wilcoxon’s test.
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patients. We identified a group of proteins candidates to
be a(1,6)fucosylated and specifically regulated in color-
ectal tumours. Validating our approach, all the identified
proteins have been described as glycoproteins, and most
of them as a(1,6)fucosylated proteins. We selected three
of them, the GRP94, the pIgR and the IgGFcBP in order
to validate their altered expression during colorectal
carcinogesis.
The GRP94 or endoplasmin is the most abundant gly-
coprotein in the endoplasmic reticulum. It belongs to
the family of the heat-shock proteins, and together with
GRP78 assists the folding and assembly of a wide range
of proteins. The GRP94 also shows ATPase activity and
plays an essential role in the cellular protection against
different stress situations. Under pathological conditions,
such as tumour growth, GRP94 is dramatically up-regu-
lated as a survival mechanism [30], being its overexpres-
sion associated with a more aggressive tumour
phenotype and a poor evolution of the disease [31,32].
In CRC, gene and protein GRP94 expression are
strongly increased in both animal models and human
tumours [33,34], and therefore GRP94 has been
proposed as a useful diagnostic and prognostic marker
for the disease. Concordantly, after an immunoblot ana-
lysis of the GRP94 expression in paired healthy and
tumour colorectal specimens, we observed a significant
increase in tumour tissue. In this sense, it is conceivable
that up-regulation of GRP94 allows the correct folding
of several oncogenic products promoting the colorectal
carcinogenesis, although this increase has also been
related with the acquisition of survival mechanisms by
tumour cells to stand up lethal conditions, such as glu-
cose starvation and hypoxia, and with the ability to form
new distant solid tumours [30]. It also important to
remark that although this protein is known to be glyco-
sylated our study suggest for the first time its a(1,6)
fucosylated status, however further studies should be
developed to demonstrate this it.
In the same band where GRP94 was detected, MS
analysis also identified the potential presence of pIgR.
This glycosylated receptor is located in the basolateral
membrane of the oral and gastrointestinal epithelial
cells. Its main function is the transport of IgA and IgM
polymeric forms across the epithelial cell membranes
[35]. Recently, the a(1,6)fucosylation of this protein has
Figure 4 pIgR expression in healthy and tumour colorectal tissues. (A) Validation of the 1D-SDS-PAGE results for pIgR by immunoblotting in
12 paired samples of healthy (H) and tumour (T) tissue. (B) The statistical analysis showed no significant differences between healthy and tumour
tissues according to Wilcoxon’s test.
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specimens [36], confirming the results obtained in our
study for colonic tissue. Interestingly, the importance of
pIgR is not restricted to immunology, since changes in
its expression, either increase or decrease, have been
described in different types of tumours [37]. However,
after our comparative immunoblot analysis between
paired specimens of healthy and tumour mucosa, no sig-
nificant differences were found in spite of the previous
studies indicating an early decrease of pIgR expression
during colorectal carcinogenesis [38]. It seems that the
absence of pIgR in the tumour cells could induce a
depletion of the immune response that promotes their
malignant potential; nevertheless, its role in cancer
development remains unknown.
Finally, we analyzed by Western blot and immunohis-
tochemistry the expression of IgGFcBP, a protein
secreted by the mucosa epithelial cells and present in
the body fluids [31]. It specifically recognizes the con-
stant fraction of IgG, and plays a relevant role in the
structural maintenance of the mucosa through the bind-
ing to the MUC2 mucin [39]. Despite the theoretical
molecular mass of IgGFcBP is ~500 kDa [31], SDS-
PAGE reports Mr ~100-80 kDa depending on the tissue
Figure 5 IgGFcBP expression in healthy and tumour colorectal tissues. (A) Validation of the 1D-SDS-PAGE results for IgGFcBP by
immunoblotting in 20-paired samples of healthy (H) and tumour (T) tissue. The Western blot allowed the visualization of two underexpressed
isoforms of ~108 and ~52 kDa. (B) For the ~108 kDa band, this decrease was statistically significant. *p < 0.05, according to Wilcoxon’s test.
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Page 9 of 12analyzed. In our study two bands of 108 and 52 kDa
were detected, suggesting a tissue specific proteolytic
process. Interestingly, the two bands showed a clear
decrease in tumour specimens, statistically significant
for the 108 KDa band. These results were confirmed by
immunohistochemistry, since a positive IgGFcBP expres-
sion was observed in all the healthy specimens analyzed,
while only 3 early staged tumours were found positive
(with the expression mainly confined to the non-infil-
trating epithelia). Concordantly with the specific expres-
sion of IgGFcBP in the goblet cells of the mucosa, the 3
positive tumours present higher percentage of mucinous
component than the other specimens. It should be of
great interest check the status of the IgGFcBP expres-
sion in mucilaginous tumours to demonstrate the inde-
pendence between the tumour histology and the
IgGFcBP downregulation. Furthermore, the analysis of 6
polyps showed expression of IgGFcBP in 4 of the
specimens. Supporting our results, the lost of expression
of this a(1,6)fucosylated protein in tumour specimens
h a sa l s ob e e nr e p o r t e di nh e p a t i ct i s s u e s[ 3 6 ]a n dt h e
same tumour decrease of IgGFcBP has been described
in animal models of CRC and human polyps [40,41].
The biological significance of the down-regulation of
IgGFcBP in tumour cells is uncertain. In this sense, the
binding between this protein and IgG could protect it
from the action of bacterial proteases [31], promoting
the immunological response of the mucosa. Thus, the
IgGFcBP overexpression has been detected in ulcerous
colitis and Cröhn patients [42]. Consequently, it is
thought that low secreted levels of this protein in tumour
cells could facilitate the immune evasion. However, the
absence of IgGFcBP in the colon mucosa could also lead
to the structural disorganization of intestinal mucus, pro-
m o t i n gt h ee x p o s u r eo fm u c o s at oc a r c i n o g e n i ca g e n t s
and, therefore, the appearance of premalignant lesions in
Figure 6 Immunohistochemistry analysis of IgGFcBP expression. (A) Healthy colon tissue with a specific IgGFcBP staining localized in the
intracellular mucus of globelet cells. (B) CRC tissue with a positive IgGFcBP staining present in the non-invasive zone. (C) Mixed hyperplastic/
adenomatous polyp with the IgGFcBP positive glands in the non dysplastic areas.
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Page 10 of 12the epithelium. Taking into account that increased levels
of serum IgGFcBP have been observed in inflammatory
processes, a possible decrease in CRC could be of great
value as a biomarker for this neoplasia.
Conclusion
In conclusion, the present study confirmed the altered
expression of GRP94 in CRC and demonstrated for the
first time its core-fucosylated status. Besides, a strong
down-regulation of the IgGFcBP associated to the dys-
plastic phenotype acquisition was determined in pre-
cancerous and cancerous lesions of colorectal mucosa.
Despite the role of both molecules in CRC must be stu-
died in depth, these results ratify the utility of screening
a(1,6)fucosylated proteins differentially expressed in
tumour colorectal mucosa as a way to identify molecules
implicated in CRC carcinogenesis and progression. This
same strategy improved with 2D-SDS-PAGE or HPLC,
could serve as an important tool for the elucidation of
novel biomarkers and/or therapeutic targets which may
facilitate the clinical management of CRC patients.
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